```html

Nervous System Vasculitis: A Comprehensive Patient Guide

Overview

Nervous system vasculitis is a group of rare inflammatory disorders in which blood vessels that supply the brain, spinal cord, or peripheral nerves become inflamed and damaged. The inflammation can lead to narrowing, blockage, or rupture of the vessels, depriving nerve tissue of oxygen and nutrients.

These conditions are often classified under vasculitis involving the central nervous system (CNS) or peripheral nervous system (PNS). They may occur as part of a systemic vasculitis (e.g., granulomatosis with polyangiitis, microscopic polyangiitis) or as a primary disease limited to the nervous system, such as primary angiitis of the central nervous system (PACNS).

Who is affected?

• Adults 40‑70 years old are most commonly diagnosed, but cases occur in children and the elderly.
• Both sexes are affected; some subtypes (e.g., Takayasu arteritis) are more common in women, while others (e.g., Kawasaki disease) predominate in children.
• People with a personal or family history of autoimmune disease (e.g., lupus, rheumatoid arthritis) have a higher risk.

Prevalence

Overall vasculitis affects <≈ 20–30 cases per 100,000 people worldwide, but isolated nervous‑system vasculitis is far rarer—estimated at <1–2 cases per million people per year.

Because symptoms often mimic stroke, migraine, or neuropathy, the true incidence may be under‑reported.

Symptoms

Symptoms depend on which part of the nervous system is involved and the size of the affected vessels. Below is a comprehensive list:

Central nervous system (brain & spinal cord)

• Headache – persistent, throbbing, or sudden “worst‑ever” headache.
• Seizures – focal or generalized, may be new‑onset.
• Focal neurological deficits – weakness or numbness in an arm/leg, difficulty speaking (aphasia), vision changes, or facial droop.
• Stroke‑like events – sudden loss of function that may improve or fluctuate.
• Encephalopathy – confusion, memory problems, or personality changes.
• Neuro‑ophthalmic signs – double vision, optic neuritis (painful vision loss), or retinal artery occlusion.
• Spinal cord syndromes – back pain with rapid onset of weakness, bladder/bowel dysfunction.

Peripheral nervous system (cranial & peripheral nerves)

• Peripheral neuropathy – symmetric or asymmetric numbness, tingling, burning, or loss of sensation.
• Mononeuritis multiplex – sudden loss of function in two or more individual nerves (e.g., foot drop, wrist drop).
• Painful neuropathy – severe, burning pain that may be worse at night.
• Autonomic dysfunction – abnormal sweating, blood pressure swings, or gastrointestinal dysmotility.

Systemic features that often accompany nervous‑system vasculitis

• Fever, night sweats, weight loss
• Malaise, fatigue
• Joint or muscle pain
• Skin lesions (purpura, livedo reticularis)
• Kidney or lung involvement when part of a systemic disease

Causes and Risk Factors

Vasculitis is not a single disease but a spectrum of immune‑mediated disorders. The exact cause is often unknown, but several mechanisms have been identified:

Immune system dysregulation

• Autoantibodies (e.g., anti‑neutrophil cytoplasmic antibodies – ANCA) target vessel walls.
• Immune complexes deposit in small vessels, triggering complement activation.
• T‑cell mediated inflammation leading to granuloma formation (as in granulomatosis with polyangiitis).

Infections

• Viral: Hepatitis B, Hepatitis C, HIV, parvovirus B19.
• Bacterial: Treponema pallidum (syphilis), Mycobacterium tuberculosis.
• Fungal or parasitic infections may precipitate vasculitis in immunocompromised hosts.

Medications & toxins

• Propylthiouracil, hydralazine, cocaine (adulterated with levamisole) can trigger ANCA‑associated vasculitis.
• Radiation therapy, certain biologic agents (e.g., anti‑TNF drugs) have been implicated.

Genetic predisposition

• HLA‑B51 is linked with Behçet’s disease, which can involve CNS vasculitis.
• Family clustering of autoimmune diseases raises susceptibility.

Risk Factors

• Existing autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis).
• Chronic infections (especially hepatitis C).
• Exposure to drugs known to cause vasculitis.
• Older age (higher risk for large‑vessel involvement).
• Smoking – increases systemic inflammation and cardiovascular risk.

Diagnosis

Because symptoms overlap with many other neurological conditions, a systematic approach is essential.

Clinical evaluation

• Detailed history (onset, progression, systemic signs, medication exposure).
• Comprehensive neurological examination.

Laboratory tests

• Complete blood count (CBC) – anemia or leukocytosis.
• Inflammatory markers: ESR and CRP (often elevated).
• Autoantibodies:
  • ANCA (p‑ANCA/MPO and c‑ANCA/PR3) – positive in 60‑80 % of ANCA‑associated vasculitis.
  • ANA, anti‑dsDNA – suggest lupus‑related vasculitis.
  • Rheumatoid factor, complement levels.
• Infection screens (HBV, HCV, HIV, syphilis serology) when appropriate.

Imaging

• MRI of brain and spine with contrast – shows vessel wall enhancement, infarcts, or leptomeningeal involvement.
• Magnetic resonance angiography (MRA) / CT angiography (CTA) – evaluates large‑ and medium‑sized vessels.
• Digital subtraction angiography (DSA) – gold standard for detecting segmental narrowing (“beading”) in small‑ to medium‑vessel disease, especially in PACNS.
• High‑resolution vessel wall MRI can differentiate vasculitis from atherosclerosis.

Biopsy

• Definitive diagnosis often requires tissue. Options:
  • Brain or meningeal biopsy (most specific, but invasive).
  • Peripheral nerve or skin biopsy if vasculitis is suspected in those tissues.
• Histology shows necrotizing inflammation of vessel walls, fibrinoid necrosis, and infiltrating neutrophils or lymphocytes.

Diagnostic criteria

Several consensus statements (e.g., 2012 International Chapel Hill Consensus) outline criteria for specific vasculitis subtypes. For primary CNS vasculitis, the 2018 American College of Rheumatology (ACR) criteria require:

1. Age ≥ 18 years.
2. Absence of systemic vasculitis or other mimicking disease.
3. Evidence of angiographic or histologic CNS vessel inflammation.

Treatment Options

Treatment aims to suppress the immune response, prevent vessel damage, and manage symptoms. Therapy is individualized based on disease severity, vessel size, and organ involvement.

Induction therapy (rapid disease control)

• Corticosteroids – high‑dose prednisone 1 mg/kg/day (max 80 mg) or IV methylprednisolone 500‑1000 mg daily for 3‑5 days in severe cases.
• Immunosuppressive agents:
  • Cyclophosphamide (IV or oral) – preferred for severe or organ‑threatening disease.
  • Rituximab (anti‑CD20 monoclonal antibody) – effective for ANCA‑associated vasculitis; 375 mg/m² weekly × 4 or 1 g biweekly × 2.
  • Mycophenolate mofetil – alternative for patients intolerant of cyclophosphamide.
  • Tocilizumab (IL‑6 blocker) – emerging data for large‑vessel vasculitis.

Maintenance therapy (prevent relapse)

• Low‑dose prednisone (≤ 10 mg/day) tapered over 6‑12 months.
• Azathioprine, mycophenolate, or methotrexate as steroid‑sparing agents.
• Rituximab re‑infusion every 6‑12 months for ANCA‑associated disease.

Adjunctive treatments

• Antiplatelet or anticoagulation when ischemic stroke has occurred, after weighing bleeding risk.
• Analgesics for neuropathic pain (gabapentin, pregabalin, duloxetine).
• Physical and occupational therapy to restore function after neurologic deficits.
• Vaccinations (influenza, pneumococcal, COVID‑19) – especially important for immunosuppressed patients.

Procedural interventions

• Endovascular angioplasty or stenting for focal large‑vessel stenosis (rare, reserved for refractory cases).
• Plasma exchange (PLEX) – considered in life‑threatening ANCA‑associated vasculitis with pulmonary‑renal syndrome or severe neurologic involvement.

Lifestyle and supportive care

• Balanced diet rich in fruits, vegetables, lean protein, and omega‑3 fatty acids to reduce inflammation.
• Regular, moderate exercise (as tolerated) improves cardiovascular health and mood.
• Avoid smoking and limit alcohol.
• Stress‑reduction techniques (mindfulness, yoga) can help with fatigue and pain.

Living with Nervous System Vasculitis

Managing a chronic, potentially relapsing disease requires a proactive, multidisciplinary approach.

Medication adherence

• Use a medication calendar or smartphone reminder.
• Never stop steroids abruptly; follow a tapering schedule prescribed by your doctor.

Monitoring

• Regular blood tests (CBC, liver/kidney function, CRP/ESR) every 1‑3 months during induction, then every 3‑6 months.
• Annual MRI or angiography if disease was previously documented in the CNS.
• Track symptoms in a journal: new headaches, weakness, visual changes, or worsening pain should be reported promptly.

Rehabilitation

• Physical therapy to improve strength and gait.
• Occupational therapy for fine motor skills and adaptive equipment.
• Speech therapy if language or swallowing is affected.

Psychosocial support

• Join support groups (e.g., Vasculitis Foundation, local patient networks).
• Consider counseling or cognitive‑behavioral therapy for anxiety or depression, which are common in chronic neurological illness.

Employment and daily activities

• Discuss reasonable accommodations with your employer (flexible hours, remote work).
• Plan for “flare‑days”—have a caregiver or colleague aware of your condition and emergency steps.

Prevention

Because many cases are idiopathic, true primary prevention is limited. However, risk reduction strategies are valuable:

• Control modifiable risk factors: quit smoking, maintain a healthy weight, manage hypertension, diabetes, and hyperlipidemia.
• Prompt treatment of infections (e.g., hepatitis C) to lower immune‑complex vasculitis risk.
• Avoid known drug triggers when possible; discuss alternatives with your physician.
• Stay up‑to‑date on vaccinations to prevent infections that could precipitate vasculitis.

Complications

If left untreated or poorly controlled, nervous system vasculitis can lead to severe, irreversible outcomes:

• Permanent neurologic deficits – chronic weakness, aphasia, visual loss.
• Recurrent strokes – increasing disability, cognitive decline.
• Seizure disorder – may become refractory to medication.
• Spinal cord infarction – paraplegia or bladder/bowel dysfunction.
• Peripheral neuropathy – debilitating pain and loss of sensation.
• Systemic organ involvement – kidney failure, lung hemorrhage, or myocardial ischemia when vasculitis is systemic.
• Medication toxicity – long‑term steroids cause osteoporosis, diabetes, cataracts; cyclophosphamide can cause bladder toxicity or secondary malignancy.
• Infections – immunosuppression raises susceptibility to bacterial, viral, and fungal infections.

When to Seek Emergency Care

---

References

1. American College of Rheumatology. 2018 Revised Criteria for the Classification of Vasculitis. Arthritis Rheumatol. 2018;70(1):158‑165.
2. Mayo Clinic. Vasculitis. https://www.mayoclinic.org (accessed 2024).
3. Cleveland Clinic. Primary Angiitis of the Central Nervous System. https://my.clevelandclinic.org (accessed 2024).
4. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Vasculitis. https://www.niams.nih.gov (accessed 2024).
5. World Health Organization. Global Health Estimates 2022: Prevalence of Rare Diseases.
6. Jennette JC, Falk RJ, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol. 2013;65(1):1‑11.
7. Vasculitis Foundation. Patient Resources and Guidelines. https://www.vasculitisfoundation.org (2023).

```